Morningstar trims outlook for Australia's CSL, urges firm to hire new CEO

Csl

11/05/2026 19:36

** Analysts at Morningstar slash revenue and underlying NPAT forecasts for biotech firm CSL CSL.AX by 3% and 9% on average over next 10 years

** Says it was hard to justify high revenue growth for CSL, given lack of sales momentum

** "There is much to do to turn CSL around" - Morningstar

** On Monday, Australia's CSL cut its annual profit forecast and warned of a $5 billion impairment

** Investment research firm says "hiring credible new CEO and unveiling a compelling vision will be important steps on the path to redemption"

** Nine of 16 analysts rate the stock "buy" or higher, seven "hold"; their median PT is A$195– data compiled by LSEG

** YTD, stock down 41.7%

(Reporting by Rajasik Mukherjee in Bengaluru)

((Rajasik.Mukherjee@thomsonreuters.com))